Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania.
| Revenue (Most Recent Fiscal Year) | $18.72M |
| Net Income (Most Recent Fiscal Year) | $-132.07M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 8.95 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.10 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -732.42% |
| Net Margin (Trailing 12 Months) | -732.42% |
| Return on Equity (Trailing 12 Months) | -30.73% |
| Return on Assets (Trailing 12 Months) | -22.74% |
| Current Ratio (Most Recent Fiscal Quarter) | 5.06 |
| Quick Ratio (Most Recent Fiscal Quarter) | 5.06 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.44 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.12 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.80 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.39 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Common Shares Outstanding | 108.28M |
| Free Float | 101.35M |
| Market Capitalization | $159.17M |
| Average Volume (Last 20 Days) | 1.27M |
| Beta (Past 60 Months) | 0.41 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 6.40% |
| Percentage Held By Institutions (Latest 13F Reports) | 98.34% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |